Hildegund Ertl
Professor, Vaccine & Immunotherapy Center at the Wistar Institute in Philadelphia, USA

From what I’ve seen out there, they are probably the most promising platform.

Ian Jones
Virology professor at Reading University, United Kingdom

There is enough general background data on recombinant adenovirus-based vaccines to assume the vaccine itself will be safe at the usual doses.

Ashwani Mahajan
National co-convener of Swadeshi Jagran Manch, India

Once the efficacy issue is resolved, then the cost would be an important issue. My feeling is that on both these accounts, the Russian vaccine would pass the test.

Message has been successfully sent!

Thank you!
You have been subscribed